

YAN SONG, PH.D.
Vice President

Office: (+1) 617 425 8272
yan.song@analysisgroup.com

111 Huntington Avenue, 14th Floor
Boston, MA 02199

Dr. Song is an epidemiologist with expertise in biostatistics and medicine, which he uses to address a wide array of analytical questions in health care. He has broad experience designing and implementing advanced and innovative real-world data analytic and economic modeling solutions for pharmaceutical and biotech clients. Dr. Song conducts research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across a variety of therapeutic areas. He is experienced in disease areas such as oncology, hematology, infectious diseases and vaccines, dermatology, rheumatology, cardiology, and endocrinology. Dr. Song has provided cross-indication consulting for multiple blockbuster pharmaceutical products as well as novel pipeline agents. In his work, he uses data from clinical trials, administrative claims, medical chart reviews, surveys, qualitative interviews, and medical literature. His research has covered many different study types, including disease epidemiology and causal inference, burden of illness, disease treatment and management patterns, comparative effectiveness research, individualized medicine, systematic literature reviews, indirect treatment comparisons, economic modeling such as cost-effectiveness analyses and budget impact analyses, analyses of patient-reported outcomes, and preference research such as discrete choice experiments. Dr. Song's work has been published in peer-reviewed journals and presented at international conferences on medical and health care research.

EDUCATION

2014	Ph.D., epidemiology, University of California, Los Angeles
2009	M.S., epidemiology and biostatistics, Peking University
2007	B.Med. (M.D.), Peking University

PROFESSIONAL EXPERIENCE

2014–Present	Analysis Group, Inc. <i>Vice President (2021–Present)</i> <i>Manager (2017–2020)</i> <i>Associate (2014–2016)</i>
2009–2014	University of California, Los Angeles <i>Research Assistant</i> <i>Teaching Assistant</i>

SELECTED PUBLICATIONS

- | | | |
|--------------------------------|--------------------------|--------------------------|
| ® Real-world database analysis | Ⓜ Medical chart review | Ⓢ Survey/interview |
| Ⓔ Economic modeling | Ⓙ Trial data-based study | Ⓛ Evidence synthesis/ITC |

Oncology and hematology

- ® Rai P, Song A, Zhang S, **Song Y**, Gao C, Jiang A, Li J, Jiang P, Signorovitch J, Arunachalam A, Samkari A, Dally ME. Clinical and economic impact of recurrence in unresected non-small cell lung cancer treated with primary stereotactic body radiotherapy: a real-world study using SEER-Medicare data. *Journal of Managed Care & Specialty Pharmacy*. 2025.
- ® Garg M, Satija A, **Song Y**, Sarpong EM, Meade B, Signorovitch J, Ryland K, Raut M. Economic burden and treatment patterns among patients with mantle cell lymphoma in the United States: a retrospective study of administrative claims data. *Current Medical Research and Opinion*. 2025.
- ® Zheng D, Zhang S, Bidali B, Lerman N, **Song Y**, Song R, Li J, Zhu A, Tang Y, Signorovitch J, Merchant S, Hanna GJ. Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States. *Frontiers in Oncology*. 2025:15.
- ® Kponee-Shovein K, Prabhu V, **Song Y**, Chen L, Cheng M, Li Y, Sun Y, Hilts A, Hua Q, Lichfield J, Duska L. Clinical burden of recurrent disease in high-risk endometrial cancer. *Oncology and Therapy*. 2025.
- ® Jonasch E, **Song Y**, Freimark J, Mohan M, Signorovitch J, Sundaram M. Disease monitoring and treatment patterns of von Hippel-Lindau disease-associated renal cell carcinoma in the United States. *Clinical Genitourinary Cancer*. 2025:23(3).
- ® Garg M, Sajita A, **Song Y**, Sarpong E, Meade B, Lemus-Wirtz E, Gaburo K, Signorovitch J, Raut M, Ryland K. Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data. *Leukemia & Lymphoma*. 2025:66(8).
- Ⓙ Lin C, Sivaraman S, Sajeev G, **Song Y**, Xu C, He C, Signorovitch J, Shin H, Tang X-Y, Zhang M-J, Burns LJ, Simantov R, Horwitz ME. Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources. *Blood Neoplasia*. 2025.
- ® Earla J, Kponee-Shovein K, Kurian A, Mahendran M, **Song Y**, Hua Q, Hilts A, Sun Y, Hirshfield K, Mejia J. Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study. *Journal of Medical Economics*. 2025:28(1).
- ® Hanna GJ, Zheng D, Gao W, Hair GM, Ai L, **Song Y**, Lerman N, Bidadi B, Zion A, Zou L, Tang Y, Wang L, Merchant S, Black CM. PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S. *Oral Oncology*. 2025:161.
- ® Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, **Song Y**, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA. Correlation between disease-free survival endpoints and overall survival in elderly patients with early-stage HER2-negative breast cancer: a SEER-Medicare analysis. *Advances in Therapy*. 2025:42(2).

- ® Prabhu VS, Kponee-Shovein K, Cheng M, Hong J-L, **Song Y**, Sun Y, Hilts A, Hua Q, Lichfield J, Duska L. Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study. *Journal of Medical Economics*. 2024:27(1).
- ® Donington J, Hu X, Zhang S, **Song Y**, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Real-world neoadjuvant treatment patterns and outcomes in resected non-small cell lung cancer. *Clinical Lung Cancer*. 2024:25(5).
- ® Khera N, Edwards ML, **Song Y**, Sun R, Manghani R, Shin H, Simantov R, Signorovitch J, Sivaraman S, Gergis U. Projected impact of omidubicel-only on racial/ethnic disparities in allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in hematologic malignancies. *Advances in Therapy*. 2024:41(4).
- ® Jonasch E, **Song Y**, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and economic burden of von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. *Orphanet Journal of Rare Diseases*. 2024:19(1).
- ® Maziarz R, Gergis U, Edwards ML, **Song Y**, Liu Q, Anderson A, Signorovitch J, Manghani R, Simantov R, Shin H, Sivaraman S. Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. *Blood Advances*. 2024:8(5).
- ® Donington J, Hu X, Zhang S, **Song Y**, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy. *The Journal of Thoracic and Cardiovascular Surgery*. 2024:168(4).
- ® Saini L, Griffin JD, Pandya BJ, Shah MV, Zhou M, Yang H, **Song Y**, Marshall DA. Patient and physician preferences for acute myeloid leukemia maintenance treatments following hematopoietic stem cell transplantation. *Patient Preference and Adherence*. 2023:17.
- ® West H, Hu X, Zhang Su, **Song Y**, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer. *Journal of Managed Care & Specialty Pharmacy*. 2023:29(7).
- ® Jonasch E, **Song Y**, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. Epidemiology and economic burden of von Hippel-Lindau disease-associated renal cell carcinoma in the United States. *Clinical Genitourinary Cancer*. 2023:21(2).
- ® West H, Hu X, Zhang Su, **Song Y**, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A. Treatment patterns and outcomes in resected early-stage non-small cell lung cancer: An analysis of the SEER-Medicare data. *Clinical Lung Cancer*. 2023:24(3).
- ® Hass N, **Song Y**, Willemann-Rogerio J, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M. Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. *International Journal of Urology*. 2023:30(3).

- ① Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Maziarz RT, Hwang YK, **Song Y**, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz ME, Sung AD. Health-related quality of life following allogeneic hematopoietic cell transplantation with omidubicel versus umbilical cord blood. *Transplantation and Cellular Therapy*. 2023:29(1).
- Ⓡ Sundaram M, **Song Y**, Willemann-Rogerio J, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu J, Signorovitch J, Haas NB. Clinical and economic burdens of recurrence following nephrectomy for intermediate-high or high-risk renal cell carcinoma: a retrospective analysis of SEER-Medicare data. *Journal of Managed Care & Specialty Pharmacy*. 2022:28(10).
- ① Hamadani M, Chen L, **Song Y**, Xu MK, Liao L, Caimi PF, Carlo-Stella C. Matching-adjusted indirect comparison of the efficacy of loncastuximab tesirine versus treatment in the chemoimmunotherapy era for relapsed/refractory diffuse large B-cell lymphoma. *Clinical Lymphoma, Myeloma & Leukemia*. 2022:22(8).
- Ⓡ Sieluk J, **Song Y**, Freimark J, Huang M, Haiderali A, Berman R, Wang T, Signorovitch J, Hirshfield KM. The economic burden of recurrence in triple-negative breast cancer among working age patients in the United States. *Advances in Therapy*. 2021:39(2).
- Ⓜ Griffin JD, **Song Y**, Yang H, Freimark J, Shah MV. Posttransplant maintenance therapy in patients with *FLT3*-mutated acute myeloid leukemia: real-world treatment patterns and outcomes. *European Journal of Haematology*. 2021:107(5).
- Ⓔ Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, **Song Y**, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. *Current Medical Research and Opinion*. 2020:36(9).
- Ⓔ Bensimon AG, Zhou Z-Y, Jenkins M, **Song Y**, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma in the United States. *Clinical Drug Investigation*. 2020:40(7).
- Ⓡ Schultz NM, Penson DF, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. Adverse events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. *Drug Safety*. 2019:43(1).
- Ⓔ Bensimon AG, Zhou Z-Y, Jenkins M, **Song Y**, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. *Journal of Medical Economics*. 2019:22(10).
- Ⓡ Schultz N, Penson D, Wilson S, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. *Journal of Managed Care & Specialty Pharmacy*. 2019:25(8).
- Ⓜ Griffin JD, Yang H, **Song Y**, Kinrich D, Shah M, Bui CN. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild type acute myeloid leukemia: a medical chart study. *European Journal of Haematology*. 2018:102(4).

- ® Schultz NM, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Kassabian V. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naïve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: A retrospective claims analysis. *Advances in Therapy*. 2018;35(10).
- ⓔ Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, **Song Y**, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide vs abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *Journal of Medical Economics*. 2017;20(2).
- ® **Song Y**, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ. Clinical outcomes with first-line endocrine therapy or chemotherapy in postmenopausal HR+/HER2– metastatic breast cancer. *Breast Cancer: Basic and Clinical Research*. 2015;9.
- ® **Song Y**, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. *The Journal of Nutrition*. 2013;143(2)

Immunology

- Ⓢ Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, **Song Y**, Wright GC. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. *Arthritis Research & Therapy*. 2022;24(1).
- Ⓢ Strand V, Tundia N, Bergman M, Ostor A, Durez P, Song I-H, Enejosa J, Schlacher C, **Song Y**, Fleischmann R. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. *Rheumatology*. 2021;60(12).
- Ⓢ Pope J, Sawant R, Tundia N, Du EX, Qi CZ, **Song Y**, Tang P, Betts KA. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. *Advances in Therapy*. 2020;37(5).
- Ⓢ Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, **Song Y**, Pope J. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. *Arthritis Research & Therapy*. 2019;21(1).
- ® **Song Y**, Betts KA, Lu Y, Singh R, Clewell J, Griffith J. Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis. *Rheumatology and Therapy*. 2019;6(2).
- Ⓢ Strand V, Husni ME, Betts KA, **Song Y**, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A. Network meta-analysis and cost per responder of targeted immunomodulators in the treatment of active psoriatic arthritis. *BMC Rheumatology*. 2018;2(1).
- ® Strand V, Tundia N, **Song Y**, Macaulay D, Fuldeore M. Economic burden of patients with inadequate response to targeted immunomodulators in rheumatoid arthritis. *Journal of Managed Care & Specialty Pharmacy*. 2018;24(4).

- ⑤ Husni ME, Betts KA, Griffith J, **Song Y**, Ganguli A. Benefit-risk trade-offs for treatment decision in moderate-to-severe rheumatoid arthritis: Focus on the patient perspective. *Rheumatology International*. 2017;37(9).
- ① Betts KA, Griffith J, **Song Y**, Mittal M, Joshi A, Wu EQ, Ganguli A. Network meta-analysis and cost per responder of tumor necrosis factor- α and interleukin inhibitors in the treatment of active ankylosing spondylitis. *Rheumatology and Therapy*. 2016;3(2).

Infectious diseases and vaccines

- ® Liu G, Done N, **Song Y**, Goswami H, Wang T, Li H, Mattera M, Signorovitch J, Hair GM. Healthcare resource use and costs among patients with COVID-19 in the United States. *BMC Health Services Research*. 2025:25.
- ® Eiden AL, Liu Q, Choi Y, **Song Y**, Marshall GS, Done N, Wang T, Bencina G, Signorovitch J. Temporal trends in vaccination and antibiotic use among young children in the United States, 2000-2019. *Antimicrobial Stewardship & Healthcare Epidemiology*. 2025:5(1).
- ① Huang M, Xie J, Romdhani H, **Song Y**, Lee S, Liu D, Elbasha E, Mohanty S, Rowen D, Kelly MS. Global assessment of health utilities associated with pneumococcal disease in children — targeted literature review. *Pharmacoeconomics*. 2025.
- ® Oluwaseun S, Yang C, Si Tu SJ, Yin J, **Song Y**, Sun Q, Kanibir N, Hartwig S, Carias C. Health impact of rotavirus vaccination in China. *Human Vaccines & Immunotherapeutics*. 2024:20(1).
- ⑤ Russell ES, Zhou M, **Song Y**, Barak N, Gao Y, Mast TC. Patterns of HIV treatment preferences among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States. *Journal of Acquired Immune Deficiency Syndromes*. 2024.
- ® Mohanty S, Done N, Liu Q, **Song Y**, Wang T, Gaburo K, Sarpong EM, White M, Weaver J, Signorovitch J, Weiss T. Incidence of pneumococcal disease in children ≤ 48 months old in the United States: 1998-2019. *Vaccine*. 2024:42(11).
- ® Hu T, **Song Y**, Done N, Mohanty S, Liu Q, Sarpong EM, Lemuz-Wirtz E, Signorovitch J, Weiss T. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018. *BMC Health Services Research*. 2023:23(1).
- ® Igho-Osagie E, Puenpatom A, Williams MG, **Song Y**, Yi D, Wang J, Berman R, Gu M, He C. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy. *Journal of Managed Care & Specialty Pharmacy*. 2023:29(5).
- ® Hu T, Sarpong EM, **Song Y**, Done N, Liu Q, Lemuz-Wirtz E, Signorovitch J, Mohanty S, Weiss T. Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: A retrospective claims database analysis. *Pneumonia*. 2023:15(1).
- ® Hu T, **Song Y**, Done N, Liu Q, Sarpong E, Lemuz-Wirtz E, Signorovitch J, Mohanty S, Weiss T. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018. *BMC Public Health*. 2022:22(1).

- ® Hu T, Done N, Petigara T, Mohanty S, **Song Y**, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E, Weiss T. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018. *BMC Infectious Disease*. 2022;22(1).
- ® Yamazaki K, Macaulay D, **Song Y**, Gonzalez YS. Clinical and economic burden of patients with chronic hepatitis C with versus without antiviral treatment in Japan: an observational cohort study using hospital claims data. *Infectious Diseases and Therapy*. 2019;8(2).
- Ⓐ Signorovitch JE, Betts KA, **Song Y**, Sorg RA, Li J, Behl AS, Kalsekar A. Comparative efficacy and safety of daclatasvir/asunaprevir versus interferon-based regimens in genotype 1b HCV infection. *Journal of Comparative Effectiveness Research*. 2015;4(6).

Cardiology and endocrinology

- Ⓜ Greene SJ, Gaggin HK, Bash L, Lautsch D, **Song Y**, Zhou M, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Cardiologist-reported reasons for not titrating guideline-directed medical therapy for heart failure with reduced ejection fraction. *Journal of Cardiac Failure*. 2025.
- ® Lv L, Wang Y, Xie L, Noone J, Alvarez S, Zhang Y, **Song Y**, Rotroff DM. Newer GLP-1 RAs are associated with improved glycemic control in US adults with type 2 diabetes: a population-level time series analysis. *Value in Health*. 2025;28(5).
- Ⓜ Gaggin HK, Greene SJ, Zhou M, Lautsch D, Bash LD, Djatche L, **Song Y**, Signorovitch J, Stevenson AS, Blaustein R, Butler J. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study. *International Journal of Cardiology Cardiovascular Risk and Prevention*. 2024;21.
- Ⓜ Greene SJ, Gaggin HK, Zhou M, Bash LD, Lautsch D, Djatche L, **Song Y**, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Treatment patterns of patients with worsening heart failure with reduced ejection fraction. *ESC Heart Failure*. 2024;11(4).
- ® Li J, Yang Q, Zhong F, Manson JE, Papandonatos GD, Wu W-C, Chan K-H, **Song Y**, Kuang J, Liu S. Prenatal exposure to famine and the development of diabetes later in life: An age-period-cohort analysis of the China Health and Nutrition Survey (CHNS) from 1997 to 2015. *European Journal of Nutrition*. 2023;62(2).
- Ⓜ Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, **Song Y**, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. *American Heart Journal*. 2022;251.
- Ⓔ Kim N, Wang J, Burudpakdee C, **Song Y**, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. *Journal of Managed Care & Specialty Pharmacy*. 2022;28(7).
- ® Li J, Sesso H, Zhong VW, Chan K-H, Madsen TE, Papandonatos GD, Zheng T, Wu W-C, **Song Y**, Yu X, Liu S. Famine and trajectories of body mass index, waist circumference, and blood pressure in two generations: Results from the China Health and Nutrition Survey (CHNS) from 1993–2005. *Hypertension*. 2022;79(3).

- ® **Song Y**, Cho M, Brennan K, Chen BH, Song Y, Manson JE, Hevener AL, You NC, Butch AW, Liu S. Relations of sex hormone levels to leukocyte telomere length in black, Hispanic, and Asian/Pacific Islander postmenopausal women. *Journal of Diabetes*. 2018:10(6).
- Ⓐ **Song Y**, Chou EL, Baecker A, You NC, Song Y, Sun Q, Liu S. Endocrine-disrupting chemicals, risk of type 2 diabetes, and diabetes-related metabolic traits: A systematic review and meta-analysis. *Journal of Diabetes*. 2015:8(4).
- ® Hu Y, **Song Y**, Franke AA, Hu FB, van Dam RM, Sun Q. A prospective investigation of the association between urinary excretions of dietary lignan metabolites and weight change in US women. *American Journal of Epidemiology*. 2015:182(6).
- ® **Song Y**, Huang YT, Song Y, Hevener AL, Ryckman KK, Qi L, LeBlanc ES, Kazlauskaitė R, Brennan KM, Liu S. Birthweight, mediating biomarkers and the development of type 2 diabetes later in life: A prospective study of multi-ethnic women. *Diabetologia*. 2015:58(6).
- ® **Song Y**, Hauser R, Hu FB, Franke AA, Liu S, Sun Q. Urinary concentrations of bisphenol A and phthalate metabolites and weight change: A prospective investigation in US women. *International Journal of Obesity*. 2014:38(12).
- ® Ryckman KK, Rillamas-Sun E, Spracklen C, Wallace RB, Garcia L, Tylavsky FA, Howard BV, Liu S, **Song Y**, LeBlanc ES, White MV, Parikh NI, Robinson JG. Ethnic differences in the relationship between birth weight and type 2 diabetes mellitus in postmenopausal women. *Diabetes & Metabolism*. 2014:40(5).
- ® He L, Tang X, **Song Y**, Li N, Li J, Zhang Z, Liu J, Yu L, Xu H, Zhang J, Hu Y. Prevalence of cardiovascular disease and risk factors in a rural district of Beijing, China: A population-based survey of 58,308 Residents. *BMC Public Health*. 2012:12.
- ® Wang F, Wu S, **Song Y**, Tang X, Marshall R, Liang M, Wu Y, Qin X, Chen D, Hu Y. Waist circumference, body mass index and waist to hip ratio for prediction of metabolic syndrome in Chinese. *Nutrition, Metabolism & Cardiovascular Diseases*. 2009:19(8).

Other therapeutic areas

- Ⓢ Chamberlain C, Morga A, **Song Y**, Edwards ML, Anderson A, Sarathy K, Christensen D, Iannaccone A, Su J. Impact of dry age-related macular degeneration on daily activities and quality of life: interview findings from patients and caregivers relative to a general population. *Clinical Ophthalmology*. 2025:18.
- Ⓜ Mao J, **Song Y**, Cheng M, Xu C, Boca A, Dandurand A, Takahashi K. Seizure burden and healthcare resource utilization among people living with drug-resistant focal epilepsy in the United States. *Current Medical Research and Opinion*. 2024:40(10).
- Ⓜ Mao J, Takahashi K, Cheng M, Xu C, Boca A, **Song Y**, Dandurand A. Real world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States. *Epilepsia Open*. 2024:9(4).
- ® **Song Y**, Wang Y, Wong SL, Yang D, Sundar M, Tundia N. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. *Multiple Sclerosis and Related Disorders*. 2023:79.

- ® **Song Y**, E J-Y, Guo T, Sasane R, Arcona S, Keshava N, Wu E. Treatment patterns and healthcare resource use in Medicare beneficiaries with Parkinson's disease. *ClinicoEconomics and Outcomes Research*. 2023:15.
- ® Fishman J, Kalilani L, **Song Y**, Swallow E, Wild I. Antiepileptic drug titration and related health care resource use and costs. *Journal of Managed Care & Specialty Pharmacy*. 2018:24(9).
- ® Wing VK, **Song Y**, Xiang C, Liu X, Macaulay D, Ponsillo M, Blumentals WA. Incidence of catheter-related complications in Japanese patients with central venous catheters and among patients with short bowel syndrome. *Clinical and Experimental Gastroenterology*. 2018:11.
- ® **Song Y**, You NC, Song Y, Kang MK, Hou L, Wallace R, Eaton CB, Tinker LF, Liu S. Intake of small-to-medium-chain saturated fatty acid is associated with peripheral leukocyte telomere length in postmenopausal women. *The Journal of Nutrition*. 2013:143(6).
- ® Cao Y, Kenfield S, **Song Y**, Rosner B, Qiu W, Sesso HD, Gaziano JM, Ma J. Cigarette smoking cessation, total and cause-specific mortality: A 22-year follow-up study in US male physicians. *Archives of Internal Medicine*. 2011:171(21).

SELECTED CONFERENCE PRESENTATIONS

Oncology and hematology

- ® Zheng D, Zhang S, Bidadi B, Lerman N, Tang Y, **Song Y**, Song R, Li J, Zhu A, Merchant S, Signorovitch J, Hanna GJ. "Real-world recurrence and survival in LA HNSCC treated with surgery and adjuvant radiotherapy with or without systemic therapy: a SEER-Medicare analysis." American Society of Clinical Oncology (ASCO) Quality Care Symposium, Chicago, IL (October 10–11, 2025)
- ® Lukas RV, Narayan VK, Freimark J, **Song Y**, Wang T, Chen Z, Chukwueke J, Sundaram M, Perini R, Shinde R. "The impact of belzutifan on tumor reduction procedures and healthcare resource utilization in von Hippel-Lindau (VHL) disease." Kidney Cancer Research Summit (KCRS), Boston, MA (July 17–18, 2025)
- ® Narayan VK, Lukas RV, Freimark J, **Song Y**, Wang T, Chen Z, Chukwueke J, Sundaram M, Perini R, Shinde R. "Real-world characteristics and treatment patterns in belzutifan-treated patients with von Hippel-Lindau (VHL) disease." KCRS, Boston, MA (July 17–18, 2025)
- ® Lotan Y, Bhattacharya R, Fang H, Chang SS, Lai Y, Zhang S, Li J, Shen P, Gao W, **Song Y**, Dave H, Li H. "Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A SEER-Medicare study." ASCO Annual Meeting, Chicago, IL (May 30–June 3, 2025)
- ® Mehta N, Wang L, Kamble S, **Song Y**, Gao E, Malhotra U, Lax A, Sundaresan S, Zhang A, Siegel A. "Economic burden of recurrence in early-stage hepatocellular carcinoma (HCC) treated with curative intent: a retrospective analysis of SEER-Medicare data." ASCO Annual Meeting, Chicago, IL (May 30–June 3, 2025)

- ® Squires P, Cook EE, **Song Y**, Wang J, Jiang A, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. “Real-world cancer recurrence and overall survival outcomes in muscle-invasive bladder cancer (MIBC) patients treated with radical cystectomy (RC): a retrospective Surveillance, Epidemiology, and End Results-Medicare study.” International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Montreal, Canada (May 13–16, 2025)
- ® Lai Y, Hill-McManus DJ, Squires P, Cook E, **Song Y**, Wang C-Y, Seshasayee S, Mamtani R. “Real-world disease management costs for U.S. patients with muscle invasive bladder cancer (MIBC) following radical cystectomy (RC) in contemporary practice.” ISPOR, Montreal, Canada (May 13–16, 2025)
- ® Zheng D, Zhang S, Bidadi B, Lerman N, **Song Y**, Song R, Li J, Zhu A, Tang Y, Signorovitch J, Merchant S, Hanna GJ. “Economic and clinical burden of recurrence among elderly patients with resected locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US.” ISPOR, Montreal, Canada (May 13–16, 2025)
- ® Bhattacharya R, Fang H, Lai Y, Zhang S, Li J, Shen P, Gao W, **Song Y**, Dave H, Li H, Lotan Y. “Economic burden of recurrence among patients with high-risk non-muscle-invasive bladder cancer who received Bacillus Calmette-Guérin in the United States: A SEER-Medicare Study.” ISPOR, Montreal, Canada (May 13–16, 2025)
- Ⓛ Chen L, Kponee-Shovein K, Liu J, **Song Y**, Hua Q, Liu J, Del Fava E, Yamada K, Burcu M. “Progression-free survival (PFS) as a surrogate for overall survival (OS) in the front-line maintenance setting for advanced ovarian cancer (OC): a trial-level meta-analysis.” ISPOR, Montreal, Canada (May 13–16, 2025)
- Ⓛ Bhattacharya R, Kponee-Shovein K, Gao Y, **Song Y**, Liu J, Wei K, Li H, Kamat AM. “Strong association between event-free survival and overall survival in BCG-naïve high-risk non-muscle invasive bladder cancer: A meta-analysis of surrogate endpoints.” Annual European Association of Urology (EAU) Congress, Madrid, Spain (March 21–24, 2025)
- ® Babcock A, Gao W, Shinde R, Gao Y, Wang T, Hua Q, **Song Y**, Signorovitch J, Zhang S. “Disease management costs and healthcare resource utilization by progression health state among patients with previously untreated locally advanced or metastatic urothelial cancer.” ASCO Genitourinary Cancers Symposium (ASCO-GU), San Francisco, CA (February 13–15, 2025)
- ® Squires P, Cook, EE, **Song Y**, Wang C-Y, Jiang A, Zhang AZ, Li H, Rogiers A, Mamtani R. “Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer (MIBC) treated with radical cystectomy: A retrospective administrative claims analysis.” Academy of Managed Care Pharmacy (AMCP) Nexus, Las Vegas, NV (October 14–17, 2024)
- ® Zheng D, Zhang S, Bidadi B, Lerman N, **Song Y**, Song R, Li J, Zhu A, Tang Y, Signorovitch J, Merchant S, Hanna GJ. “Real-world event-free survival (rwEFS) and overall survival (rwOS) in elderly patients with resected locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US.” ASCO Quality Care Symposium, San Fransisco, CA (September 27–28, 2024)

- ® Daly ME, Rai P, Zhang S, **Song Y**, Jiang A, Li J, Jiang P, Gao C, Signorovitch J, Arunachalam A, Song A, Samkari A. “Real-world clinical outcomes and the association between EFS and OS in early-stage NSCLC treated with primary SBRT.” World Conference on Lung Cancer (WCLC), San Diego, CA (September 7–10, 2024)
- ® Jonasch E, **Song Y**, Freimark J, Mohan M, Signorovitch J, Sundaram M. “Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb).” ASCO Annual Meeting, Chicago, IL (May 31–June 4, 2024)
- ® Zheng D, Zhang S, Bidadi B, Lerman N, **Song Y**, Song R, Li J, Zhu A, Tang Y, Signorovitch J, Merchant S, Hanna GJ. “Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US.” ASCO Annual Meeting, Chicago, IL (May 31–June 4, 2024)
- ① Squires P, **Song Y**, Wu A, Gao Y, Xu C, Ritesh S, Kataria RS, Li H, Sternberg CN. “Trial-level evaluation of event-free survival as a surrogate endpoint for overall survival in muscle-invasive bladder cancer following neoadjuvant therapy.” ASCO Annual Meeting, Chicago, IL (May 31–June 4, 2024)
- ® Robson M, Earla JR, Kponee-Shovein K, **Song Y**, Mahendran M, Hua Q, Hilts A, Hirshfield KM, Mejia JA, Kurian AW. “Correlation between disease free survival (DFS) endpoints and overall survival (OS) in elderly patients with human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (eBC).” European Society for Medical Oncology (ESMO) Breast Cancer, Berlin, Germany (May 15–17, 2024)
- ® Prabhu VS, Kponee-Shovein K, Hong J-L, **Song Y**, Cheng M, Sun Y, Hua Q, Hilts A, Lichfield J, Duska L. “Economic burden of disease recurrence in elderly patients with high-risk endometrial cancer (HR-EC) receiving adjuvant therapy (AT).” ISPOR, Atlanta, GA (May 5–8, 2024)
- ® Earla JR, Kurian AW, Kponee-Shovein K, **Song Y**, Mahendran M, Hua Q, Hilts A, Hirschfield KM, Mejia JA. “Economic burden of disease recurrence in elderly patients with human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (eBC).” ISPOR, Atlanta, GA (May 5–8, 2024)
- ® Kponee-Shovein K, Prabhu VS, **Song Y**, Hong J-L, Cheng M, Sun Y, Hilts A, Hua Q, Lichfield JK, Duska LR. “Real-world perioperative treatment patterns and overall survival among patients with high-risk endometrial cancer.” European Congress on Gynecological Oncology (ESGO) Congress, Barcelona, Spain (March 7–10, 2024)
- ® Prabhu VS, Kponee-Shovein K, **Song Y**, Chen L, Cheng M, Sun Y, Hilts A, Hua Q, Lichfield JK, Duska LR. “Disease free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant therapy.” Society of Gynecologic Oncology (SGO) Annual Meeting, San Diego, CA (March 16–18, 2024)
- ® Mehta N, Desai K, Kamble S, **Song Y**, Gao E, Malhotra U, Lax A, Sundaresan S, Downes N, Zhang A, Siegel A. “Real-world correlation of RFS and OS in early-stage hepatocellular carcinoma treated with curative intent: a retrospective analysis of SEER-Medicare data.” ASCO Gastrointestinal Cancers Symposium (ASCO-GI), San Francisco, CA (January 18–20, 2024)

- ® Kponee-Shovein K, Prabhu VS, **Song Y**, Chen L, Cheng M, Li Y, Sun Y, Hiltz A, Hua Q, Lichfield J, Dunska L. “Disease free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant chemotherapy.” American Association for Cancer Research (AACR) Special Conference On Endometrial Cancer, Boston, MA (November 16–18, 2023)
- ® Earla JR, Kurian AW, Kponee-Shovein K, Satija A, **Song Y**, Downes N, Mahendran M, Hua Q, Kumar A, Mejia JA. “Real-world treatment patterns in elderly patients with HER2-negative early breast cancer.” San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX (December 5–9, 2023)
- ① Pierce K, Wang Y, Malik AA, Cook EE, **Song Y**, Quintana A, Mohan T, Valdes CR, Otero PR. “Humanistic, clinical, and economic burden in patients with relapsed or refractory multiple myeloma on second line or higher therapy: a systematic literature review.” International Myeloma Society (IMS) Annual Meeting, Athens, Greece (September 27–30, 2023)
- ® Donington J, Hu X, Zhang S, **Song Y**, Gao C, Arunachalam A, Chirovsky D, Lerner A, Jiang A, Signorovitch J, Samkari A. “Real-world primary treatment patterns in stages I-III non-small cell lung cancer.” WCLC, Singapore (September 9–12, 2023)
- ® Donington J, Hu X, Zhang S, **Song Y**, Gao C, Arunachalam A, Chirovsky D, Lerner A, Jiang A, Signorovitch J, Samkari A. “Neoadjuvant treatment pattern and association between real-world event-free survival and overall survival in patients with resected early-stage non-small cell lung cancer.” European Lung Cancer Congress (ELCC) Scientific Committee, Copenhagen, Denmark (March 29–April 1, 2023)
- ® Wang L, Bensimon AG, Sundaram M, Xu R, Lai J, Liu Y, Mt-Isa S, Yang D, Freimark J, **Song Y**, Jonasch E. “Burden of surgeries and surgical complications in patients with von Hippel Lindau (VHL) disease before and after treatment with belzutifan.” ASCO Genitourinary Cancers Symposium (ASCO-GU), San Francisco, CA (February 16–18, 2023)
- ® Garg M, Satija A, **Song Y**, Sarpong E, Meade B, Lemus-Wirtz E, Gaburo K, Signorovitch J, Raut M, Ryland K, Chakraborty S. “Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.” Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA (December 10–13, 2022)
- ® Garg M, Satija A, **Song Y**, Sarpong E, Meade B, Lemus-Wirtz E, Gaburo K, Signorovitch J, Raut M, Ryland K, Chakraborty S. “Economic burden and treatment patterns among patients with mantle cell lymphoma in the US: a retrospective claims analysis.” ASH Annual Meeting, New Orleans, LA (December 10–13, 2022)
- ① Sivaraman S, Sajeew G, **Song Y**, Xu C, He C, Signorovitch J, Shin H, Manghani R, Tang X, Zhang M-J, Burns LJ, Simantov R. “Clinical outcomes following allogeneic hematopoietic cell transplantation with omidubicel or other donor sources in patients with hematologic malignancies: comparison of clinical trial results to Center for International Blood and Marrow Transplant Research database controls.” ASH Annual Meeting, New Orleans, LA (December 10–13, 2022)
- ® Lai Y, **Song Y**, Zhang S, Bhattacharya R, Carley C, Bensimon A. “Disease management costs for patients with intermediate-high or high-risk renal cell carcinoma (RCC) following nephrectomy.” ISPOR Europe, Vienna, Austria (November 6–9, 2022)

- ® West H, Hu X, Chirovsky D, **Song Y**, Zhang S, Gao C, Carley C, Lerner A, Signorovitch J, Samkari A. “Real-world disease-free survival as a predictor of overall survival in resected early-stage non-small cell lung cancer.” WCLC, Vienna, Austria (August 6–9, 2022)
- ® Haas NB, Bhattacharya R, **Song Y**, Willemann-Rogerio J, Zhang S, Carley C, Anderson A, Signorovitch J, Sundaram M. “Variation in recurrence rate and overall survival (OS) outcomes by disease stage and incremental impact of time to recurrence on OS in localized renal cell carcinoma (RCC).” ASCO Annual Meeting, Chicago, IL (June 4–6, 2022)
- ® Sundaram M, **Song Y**, Freimark J, Berman R, Nguyen H, Signorovitch J, Jonasch E. “Real-world treatment patterns in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC): costs of tumor reduction procedures and their complications.” ASCO Annual Meeting, Chicago, IL (June 4–6, 2022)
- ® Maziarz RT, Edwards ML, Gergis U, **Song Y**, Liu Q, Noman A, Anderson A, Simantov R, Manghani R, Sivaraman S, Signorovitch J. “Total costs of care and complication rates among patients with hematologic malignancies who receive allogeneic hematopoietic cell transplants in the US.” Tandem Meetings – Transplantation & Cellular Therapy Meetings of the Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), Salt Lake City, UT (April 23–26, 2022)
- ® Gergis U, Khera N, Edwards ML, **Song Y**, Sun R, Simantov R, Sivaraman S, Manghani R, Signorovitch J. “Projected impact of omidubicel on racial and ethnic disparities in allogeneic hematopoietic cell transplant access and outcomes for patients with hematologic malignancies in the US.” Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Salt Lake City, UT (April 23–26, 2022)
- ① Horwitz ME, Sajeev G, Stiff P, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Mariarz RT, Hwang WYK, **Song Y**, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Galamidi-Cohen E. “Health-related quality of life (HRQL) following transplantation with omidubicel versus umbilical cord blood (UCB) in patients with hematologic malignancies: Results from a phase III randomized, multicenter study.” Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Salt Lake City, UT (April 23–26, 2022)
- ® Jonasch E, **Song Y**, Freimark J, Berman R, Nguyen H, Signorovitch J, Sundaram M. “Healthcare resource utilization (HRU) and costs among patients with Von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC): A retrospective administrative claims analysis.” ASCO-GU, San Francisco, CA (February 17–19, 2022)
- © Zhou M, Yang H, **Song Y**, Marshall DA, Griffin JD, Saini L, Shah MV. “Patient and physician preferences for treatment of newly diagnosed acute myeloid leukemia (AML) in patients not candidates for intensive chemotherapy.” ASH Annual Meeting, Atlanta, GA (December 11–14, 2021)
- © Zhou M, Yang H, **Song Y**, Marshall DA, Griffin JD, Saini L, Shah MV. “Impact of blood transfusions on treatment attributes, quality of life, and out-of-pocket costs in newly diagnosed acute myeloid leukemia ineligible for high-intensity chemotherapy: patient and physician perspectives.” AMCP Nexus, Denver, CO (October 18–21, 2021)

- ⑤ Zhou M, Yang H, **Song Y**, Marshall DA, Griffin JD, Saini L, Shah MV. “Patient and physician perspectives on treatment attributes and the humanistic and economic burden of blood transfusions in patients with acute myeloid leukemia (AML) previously treated with hematopoietic stem cell transplantation (HSCT).” AMCP Nexus, Denver, CO (October 18–21, 2021)
- ⑤ Zhou M, Yang H, **Song Y**, Marshall DA, Griffin JD, Saini L, Shah MV. “Patient and physician preferences for post-hematopoietic stem cell transplantation maintenance treatment of acute myeloid leukemia.” European Hematology Association (EHA), Virtual Congress (June 9–17, 2021)
- ® Haas NB, **Song Y**, Willemann-Rogerio J, Zhang S, Adejoro O, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M. “Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.” ASCO Annual Meeting, Virtual Congress (June 4–8, 2021)
- ® Sieluk K, Haiderali A, Huang M, Signorovitch J, **Song Y**, Freimark J, Berman R. “Healthcare resource utilization associated with disease recurrence among surgically-treated patients with triple-negative breast cancer.” ISPOR, Virtual Congress (May 17–20, 2021)
- ® Sieluk K, Haiderali A, Huang M, Signorovitch J, **Song Y**, Freimark J, Wang T. “Productivity costs associated with disease recurrence among surgically-treated patients with triple-negative breast cancer.” ISPOR, Virtual Congress (May 17–20, 2021)
- ® Sundaram M, **Song Y**, Willemann-Rogerio J, Zhang S, Adejoro O, Carley C, Zhu J, Signorovitch J, Haas NB. “Economic and clinical burdens of recurrence following nephrectomy for intermediate-high or high-risk renal cell carcinoma (RCC): a retrospective administrative claims analysis.” ISPOR, Virtual Congress (May 17–20, 2021)
- Ⓜ Griffin JD, **Song Y**, Yang H, Freimark J, Shah MV. “Posttransplant maintenance therapy in patients with *FLT3*-mutated (*FLT3*^{mut+}) acute myeloid leukemia (AML): Results from a retrospective chart review study.” EHA, Virtual Congress (June 11–14, 2020)
- Ⓔ Bensimon A, Zhong Y, Swami U, Briggs A, Young J, Feng Y, **Song Y**, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM. “Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.” ASCO-GU, San Francisco, CA (February 13–15, 2020)
- ® Griffin J, Shah MV, **Song Y**, Yang H, Tang W. “Economic burden of relapse after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML): A retrospective claims-based analysis.” ISPOR Europe, Copenhagen, Denmark (November 2–6, 2019)
- ® Schultz NM, Lowentritt B, Wilson SC, **Song Y**, Yang H, Ramaswamy K, Penson DF. “Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.” AMCP Annual Meeting, San Diego, CA (March 25–28, 2019)
- ® Schultz NM, Penson DF, Wilson SC, **Song Y**, Yang H, Ramaswamy K, Lowentritt B. “Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis.” ASCO-GU, San Francisco, CA (February 14–16, 2019)

- Ⓜ Griffin JD, Shah MV, **Song Y**, Yang H. “Treatment patterns and healthcare resource utilization (HRU) in patients with relapsed/ refractory (R/R) *FLT3*-mutated (*FLT3*^{mut}) and *FLT3*-wild type (*FLT3*^{wt}) acute myeloid leukemia (AML): a multi-country medical chart study.” Annual Meeting of the ASH, San Diego, CA (December 1–4, 2018)
- Ⓡ Kassabian V, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Schultz NM. “Healthcare resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate.” ASCO-GU, San Francisco, CA (February 8–10, 2018)
- Ⓡ Kassabian V, Flanders SC, Wilson S, Brown BA, **Song Y**, Yang H, Lechpammer S, Schultz NM. “Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.” ASCO-GU, San Francisco, CA (February 8–10, 2018)
- Ⓜ Griffin JD, Yang H, **Song Y**, Kinrich DB, Bui CN. “Treatment patterns and healthcare resource utilization in patients with FLT3-mut and FLT3-wt acute myeloid leukemia: a multi-country medical chart study.” Annual Meeting of the ASH, Atlanta, GA (December 9–12, 2017)
- Ⓢ Bui C, Massoudi M, Balk M, Guo J, **Song Y**, Brown B, Barlev A, Pandya BJ, Yang H. “Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer.” AMCP Annual Meeting, San Francisco, CA (April 19–22, 2016)
- Ⓢ Zhang J, **Song Y**, Zhou Z, Zhang C, Signorovitch J. “The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.” 6th European Lung Cancer Conference (ELCC), Geneva, Switzerland (April 13–16, 2016)
- Ⓜ **Song Y**, Hao Y, Macalalad A, Lin P, Signorovitch J, Wu E. “Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among postmenopausal women with recurrent HR+/HER2- metastatic breast cancer.” AMCP Annual Meeting, San Diego, CA (April 7, 2015)
- Ⓡ **Song Y**, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. “Intake of dairy products in relation to risk and survival of prostate cancer: a 28-year follow-up study.” World Cancer Congress (WCC), Montréal, Canada (August 28, 2012)

Immunology

- Ⓢ Kadakia A, **Song Y**, Fillbrunn M, Jiang A. “Cost-effectiveness analysis of upadacitinib versus alternative treatment strategies for rheumatoid arthritis with inadequate response to TNFi in the United Kingdom.” European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, Vienna, Austria (June 12–15, 2024)
- Ⓡ **Song Y**, Mittal M, Zueger P, Wang Y, Gao S, Clewell J, Jones H, Deodhar A. “Response and all-cause medical service costs in patients with ankylosing spondylitis (AS) who cycled through TNFi therapies.” AMCP Annual Meeting, San Antonio, TX (March 21–24, 2023)

- ® **Song Y**, Mittal M, Zueger P, Wang Y, Gao S, Clewell J, Nakasato P, Gibofsky A. “Real-world clinical and economic value of switching to a non-TNFi advanced therapy compared with TNFi cycling in psoriatic arthritis.” AMCP Annual Meeting, San Antonio, TX (March 21–24, 2023)
- ① Bergman M, Enejosa J, Martin N, Suboticki J, Goldschmidt D, **Song Y**, Tundia N. “Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12-week results of a Phase 3 study.” American College of Rheumatology (ACR) Convergence, Virtual Congress (November 5–9, 2020)
- ① Fleischmann R, Bergman M, Tundia N, Song I-H, Suboticki J, **Song Y**, Strand V. “Patient-reported outcomes of upadacitinib versus adalimumab use in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate: 26-Week analysis of a Phase 3 study.” American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, Atlanta, GA (November 8–13, 2019)
- ① Bergman M, Tundia N, Camp HS, Meerwein S, Schlacher C, Goldschmidt D, **Song Y**, Strand V. “Effects of upadacitinib on patient-reported outcomes after 24 weeks in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic or biologic disease-modifying anti-rheumatic drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 studies.” ACR/ARHP Annual Meeting, Atlanta, GA (November 8–13, 2019)
- ① Tzellos T, **Song Y**, Wang J, Yang H, Sing R, Calimlim B. “A longitudinal assessment of the impact of adalimumab on work productivity, skin pain, and quality of life measures among patients with hidradenitis suppurativa.” European Academy of Dermatology and Venereology (EADV), Madrid, Spain (October 9–13, 2019)
- ① Strand V, Bergman M, Tundia N, Ostor A, Durez P, Song I-H, Enejosa JJ, Schlacher C, **Song Y**, Fleischman R. “Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to methotrexate: Results from SELECT-COMPARE.” EULAR European Congress of Rheumatology, Madrid, Spain (June 12–15, 2019)
- ① Strand V, Husni E, Singh R, Betts KA, **Song Y**, Zhao J, Griffith J, Ganguli A. “Network meta-analysis of targeted immunomodulators in the treatment of psoriatic arthritis patients without prior biologic treatment.” ACR/ARHP Annual Meeting, Chicago, IL (November 3–8, 2017)
- ① Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, **Song Y**, Pope J. “Patient reported outcomes of upadacitinib: Results from biologic inadequate responders (SELECT BEYOND Phase III trial).” EULAR European Congress of Rheumatology, Amsterdam, Netherlands (June 13–16, 2018)
- ® **Song Y**, Betts KA, Singh R, Clewell J, Griffith J. “Economic evaluation of patients with psoriatic arthritis treated with adalimumab or secukinumab.” AMCP Annual Meeting, Boston, MA (April 23–26, 2018)
- ® **Song Y**, Betts KA, Singh R, Clewell J, Griffith J. “Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis.” AMCP Annual Meeting, Boston, MA (April 23–26, 2018)

- ① Strand V, Husni E, Singh R, Betts BA, **Song Y**, Griffith J, Ganguli A. “Network meta-analysis of targeted immunomodulators in the treatment of biologic-naïve psoriatic arthritis.” ACR/ARHP Annual Meeting, San Diego, CA (November 3–8, 2017)
- ① Betts KA, Woolley JM, **Song Y**, Gao W, Wu EQ. “Indirect comparison of sodium zirconium cyclosilicate versus patiomer in the treatment of hyperkalemia through 48 hours.” Kidney Week of the American Society of Nephrology (ASN), New Orleans, LA (October 31–November 5, 2017)
- Ⓜ Jemec G, **Song Y**, Yang H, Skup M, Calimlim B. “Comparison of healthcare resource utilization and costs of patients with hidradenitis suppurativa treated with adalimumab and non-biologics.” Annual Congress of the EADV, Geneva, Switzerland (September 13–17, 2017)
- ① Kimball A, Yang M, **Song Y**, Valdecantos W, Ganguli A. “Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.” Annual Meeting of the American Academy of Dermatology (AAD), Orlando, FL (March 3–7, 2017)
- ① Qureshi A, Yang M, **Song Y**, Zhang A, Sundaram M, Ganguli A. “High-value subpopulation for skin pain improvement in adalimumab-treated patients with moderate to severe hidradenitis suppurativa.” Annual Meeting of the AAD, Orlando, FL (March 3–7, 2017)
- ⑤ Husni ME, Griffith J, Betts KA, **Song Y**, Ganguli A. “Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.” ACR/ARHP Annual Meeting, Washington, DC (November 11–16, 2016)
- ① Keystone EC, Betts KA, Schlacher C, **Song Y**, Ganguli A, Griffith J. “Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.” ACR/ARHP Annual Meeting, Washington, DC (November 11–16, 2016)
- Ⓜ Strand V, Tundia N, **Song Y**, Macaulay D, Fuldeore M. “Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.” ACR/ARHP Annual Meeting, Washington, DC (November 11–16, 2016)
- ① Strand V, Husni ME, Reichmann W, Betts K, Griffith J, **Song Y**, Beppu M, Ganguli A. “Network meta-analysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis.” Annual Meeting of the AAD, Washington, DC (March 4–8, 2016)
- ① Strand V, Husni ME, Reichmann W, Betts K, Griffith J, **Song Y**, Beppu M, Ganguli A. “Network meta-analysis of tumor necrosis factor, interleukins, and phosphodiesterase-4 inhibitor in the treatment of psoriatic arthritis.” ACR/ARHP Annual Meeting, San Francisco, CA (November 7–11, 2015)

Infectious diseases and vaccines

- ① Huang M, Romdhani H, **Song Y**, Xie J, Liu D, Rowen D, Elbasha E, Mohanty S, Kelly MS. “Health utilities associated with pneumococcal diseases in children and adults in the United States: A Targeted Literature Review and Meta-Analysis.” ISPOR, Montreal, Canada (May 13–16, 2025)

- ① Huang M, Xie J, Orenstein WA, Romdhani H, **Song Y**, Elbasha E, Kelly MS. “Direct costs of pneumococcal disease in the United States — a targeted literature review.” ISPOR, Montreal, Canada (May 13–16, 2025)
- ® Mohanty S, Done N, **Song Y**, Wang T, Zion A, Li T, Reichert E, White M, Huang Y-L, Cassell K, Johnson KD, Bannietts N, Weaver JP, Feemster KA. “Incidence of all-cause acute otitis media in children by risk status in the United States, 2010-2022.” European Society for Paediatric Infectious Diseases (ESPID), Bucharest, Romania (May 26–30, 2025)
- ® Mohanty S, Done N, **Song Y**, Wang T, Zion A, Reichert E, Li T, White M, Huang Y-L, Cassell K, Johnson KD, Bannietts N, Weaver JP, Feemster KA. “Incidence of all-cause non-invasive pneumonia by age and risk status among children in the United States, 2010-2022.” ESPID, Bucharest, Romania (May 26–30, 2025)
- ® Mohanty S, Done N, **Song Y**, Wang T, Zion A, White M, Huang Y-L, Cassell K, Johnson KD, Bannietts N, Weaver JP, Feemster KA. “Incidence of invasive pneumococcal disease (IPD) in children by risk status in the United States, 2010-2022.” Pediatric Academic Societies Meeting, Honolulu, HI (April 24–28, 2025)
- ⑤ Zheng Y, Frew PM, Wang D, **Song Y**, Patterson-Lomba O, Feizi A, Li T, Eiden AL. “Developing and validating predictive models of vaccine hesitancy among parents in the United States.” National Immunization Conference, Atlanta, GA (August 12–14, 2024)
- ① Huang M, Romdhani H, Xie J, **Song Y**, Lee S, Liu D, Elbasha E, Mohanty S, Rowen D, Kelly MS. “Health-related quality of life associated with pneumococcal disease – A global targeted literature review and meta-analysis.” IDWeek, Los Angeles, CA (October 16–19, 2024)
- ® Mohanty S, Done N, Liu Q, **Song Y**, Gaburo K, Wang T, Sarpong EM, White M, Weaver J, Signorovitch J, Weiss T. “Incidence of pneumococcal disease in children ≤ 48 months old in the United States: 2010-2019 (encore).” National Immunization Conference, Atlanta, GA (August 12–14, 2024)
- ① Huang M, Xie J, Elbasha E, Mohanty S, Romdhani H, **Song Y**, Mujwara D, Kelly M. “Quality of life associated with pneumococcal diseases – A targeted literature review.” European Society of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain (April 27–30, 2024)
- ® Mohanty S, Done N, Liu Q, **Song Y**, Gaburo K, Wang T, Sarpong EM, White M, Weaver J, Signorovitch J, Weiss T. “Incidence of pneumococcal disease in children ≤ 48 months old in the United States: 2010-2019.” IDWeek, Boston, MA (October 11–15, 2023)
- ⑤ Russell ES, **Song Y**, Gao Y, Signorovitch J. “Predicted uptake of novel HIV treatment options in the United States.” IDWeek, Boston, MA (October 11–15, 2023)
- ® Liu G, Done N, **Song Y**, Goswami H, Wang T, Li H, Mattera M, Signorovitch J, Hair GM. “Healthcare resource utilization and costs among patients with COVID-19 in the United States.” IDWeek, Boston, MA (October 11–15, 2023)
- ⑤ Russell ES, Zhou M, **Song Y**, Signorovitch J, Barak N, Mast TC. “Both dose frequency and modality drive HIV treatment preferences among people living with HIV in the United States.” ISPOR, Boston, MA (May 7–10, 2023)

- ⑤ Oluwaseun S, Yang C, Si Tu SJ, **Song Y**, Han F, Gu C, Signorovitch J, Wang XC, Bian R, Carias C. “Comparative public health impact of rotavirus vaccination in China.” International Congress on Infectious Disease, Kuala Lumpur, Malaysia (November 17–20, 2022)
- ® Puenpatom A, Williams MG, **Song Y**, Yi D, Wang J, Gu M, He C, Berman R, Igbo-Osagie E. “Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies.” Annual Meeting of Making a Difference in Infectious Disease (MAD-ID), Orlando, FL (May 18–21, 2022)
- ® Zhou M, **Song Y**, Gao E, Whiteside Y, Billmyer E, Signorovitch J. “Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018.” IDWeek, Virtual Congress (September 29–October 2, 2021)
- ® Hu T, Sarpong EM, **Song Y**, Done N, Orvis E, Signorovitch J, Petigara T. “Incidence of acute otitis media in children in the United States before and after the introduction of pneumococcal conjugate vaccines (PCV7 and PCV13) during 1998-2018.” IDWeek, Virtual Congress (October 21–25, 2020)
- ® Hu T, Sarpong EM, **Song Y**, Done N, Liu Q, Signorovitch J, Petigara T. “Incidence of non-invasive pneumococcal pneumonia in children in the United States before and after introduction pneumococcal conjugate vaccines (PCV7 and PCV13) during 1998-2018.” IDWeek, Virtual Congress (October 21–25, 2020)
- ⑤ Bhagat H, Xu Y, Spalding J, **Song Y**, Zhao J, Zhou M, Fadli E, Yang H. “Patient preferences for triazole antifungals in the treatment of invasive mold infection: A discrete choice experiment.” IDWeek, Washington, DC (October 2–6, 2019)
- ① Signorovitch J, Betts K, **Song Y**, Sorg R, Li J, Behl A, Kalsekar A. “Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon-alpha/ribavirin-based regimens for patients infected with genotype 1b hepatitis C virus.” Conference of the Asian Pacific Association for the Study of the Liver (APASL), Istanbul, Turkey (March 12, 2015)

Cardiology and endocrinology

- ® Watzker A, **Song Y**, Patterson-Lomba O, Fowler C, Victores A, Dezia A, Li J, Banatwala A, Melendres-Groves L. “Mental health burden among patients with pulmonary arterial hypertension in the United States.” CHEST Annual Meeting, Chicago, IL (October 19–22, 2025)
- ® Lala A, Obi EN, Done N, Bali V, **Song Y**, Nason I, Stevenson AS, Sears E, Pfefferkorn J, Signorovitch J, Ambrosy AP. “Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials.” European Society of Cardiology (ESC) Congress, Madrid, Spain (August 29–September 1, 2025)
- ® Ambrosy AP, Obi EN, Done N, Bali V, **Song Y**, Nason I, Stevenson AS, Sears E, Pfefferkorn J, Signorovitch J, Lala A. “Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use.” ESC Congress, Madrid, Spain (August 29–September 1, 2025)

- ® Amamoo J, Wang Y, Liu H, Sundar M, **Song Y**, Xie L, Mehanna S, Noone J, Swift C, Weir M. “Changes in clinical measures among U.S. adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) receiving once-weekly semaglutide (sema OW) vs. oral antidiabetic medications (ADMs).” American Diabetes Association (ADA) Scientific Sessions, Chicago, IL (June 20–23, 2025)
- ® Tan X, Cao Y, Wang Y, Boland J, Guevarra M, Xie L, **Song Y**, Kwak MJ. “Prevalence and factors for treatment failure with sodium-glucose co-transporter 2 inhibitor (SGLT2i) in US adults with type 2 diabetes (T2D).” ADA Scientific Sessions, Chicago, IL (June 20–23, 2025)
- ® Amamoo J, Wang Y, Liu H, Sundar M, **Song Y**, Xie L, Mehanna S, Noone J, Swift C, Weir M. “Changes in HbA1c and body weight in US adults with type 2 diabetes and chronic kidney disease who received oral semaglutide.” ISPOR, Montreal, Canada (May 13–16, 2025)
- ® Amamoo J, Lv L, Wang Y, Liang Y, Boland J, Xie L, Noone J, Guevarra M, **Song Y**, Gamble C, Turchin A. “Adherence to once-weekly injectable semaglutide and associated risk factors in patients with type 2 diabetes in the United States.” AMCP Annual Meeting, Houston, TX (March 31–April 3, 2025)
- ® Greene SJ, Coyle C, Bali V, Obi E, Nason I, Done N, **Song Y**, Dunbar S. “Identifying Patient Characteristics Associated with Guideline Directed Medical Therapy Uptake and Healthcare Resource Use in Patients Newly Diagnosed with Heart Failure with Reduced Ejection Fraction in the United States.” AMCP Annual Meeting, Houston, TX (March 31–April 3, 2025)
- ® Lv L, Amamoo J, Wang Y, Liang Y, Boland J, Xie L, Noone J, Guevarra M, **Song Y**, Turchin A. “Oral semaglutide adherence and associated risk factors in patients with type 2 diabetes in the United States.” AMCP Annual Meeting, Houston, TX (March 31–April 3, 2025)
- ® Lv L, Wang Y, Xie L, Noone J, Alvarez S, Zhang Y, **Song Y**, Rotroff DM. “Impact of newer GLP-1 RAs on HbA1c in US adults with type 2 diabetes: a population-level time-series analysis.” ADA Scientific Sessions, Orlando, FL (June 21–24, 2024)
- ① Clair J, Cremer P, Klein A, Luis A, Perrin R, Portman M, Raisinghani A, **Song Y**, Wang Y, Paolini JF. “Baseline demographics and disease characteristics of patients enrolled in REgiStry Of the NATural history of recurrence periCarditis in pEdiatric and adult patients (RESONANCE).” American College of Cardiology (ACC) Annual Scientific Session & Expo, New Orleans, LA (March 4–6, 2023)
- Ⓜ Gaggin HK, Greene SJ, Zhou M, Lautsch D, **Song Y**, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. “Contemporary outpatient management of patients with and without worsening heart failure with reduced ejection fraction (HFrEF) within a single integrated system: results from electronic medical record data in the CHART-HF study.” American Heart Association (AHA) Scientific Sessions, Chicago, IL (November 5–7, 2022)
- Ⓜ Greene SJ, Gaggin HK, Zhou M, Lautsch D, **Song Y**, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. “Medication changes and reasons for no medication change among outpatients with heart failure with reduced ejection fraction: results from CHART-HF.” AHA Scientific Sessions, Chicago, IL (November 5–7, 2022)

- Ⓜ Raisinghani AB, Buckley LF, **Song Y**, Chatfield J, Wang Y, Malinowski A, Berman R, He C, Wu E, Martin DR. “Real-world experience and unmet needs in the current management of recurrent pericarditis: a physician survey and medical chart review.” ACC Annual Scientific Session & Expo, Washington, DC (April 2–4, 2022)
- Ⓜ Li J, **Song Y**, Sun C, Liu S, Li Y. “Insulin resistance as a mediator for the association of protein intake with type 2 diabetes in a Chinese population.” Annual Meeting and Expo of the Endocrine Society (ENDO), Boston, MA (April 1–4, 2016)

Other therapeutic areas/general topics

- Ⓢ Chamberlain CX, Morga A, **Song Y**, Edwards ML, Anderson A, Sarathy K, Christensen D, Su J. “The impact and burden of visual impairment in patients with dry age-related macular degeneration relative to older adults without major eye conditions: a qualitative interview study.” ISPOR, Atlanta, GA (May 5–8, 2024)
- Ⓢ Chamberlain CX, Morga A, **Song Y**, Edwards ML, Anderson A, Sarathy K, Christensen D, Su J. “The caregiver perspective on dry age-related macular degeneration: a qualitative interview study.” ISPOR, Atlanta, GA (May 5–8, 2024)
- Ⓜ Mao J, Takahashi K, Cheng M, Xu C, Boca A, **Song Y**, Dandurand A. “Treatment outcomes and healthcare resource utilization among people living with focal onset epilepsy and deemed to be drug resistant in clinical practices in the United States.” American Academy of Neurology (AAN) Annual Meeting, Denver, CO (April 13–18, 2024)
- Ⓛ Signorovitch J, Llop C, **Song Y**, Parravano S, Pathare U, Fortier S, Sheikh N. “Identifying relevant clinical regulatory and health technology assessment (HTA) precedents via artificial intelligence (AI).” ISPOR Europe, Copenhagen, Denmark (November 12–15, 2023)
- Ⓜ Mao J, Takahashi K, Cheng M, Xu C, Boca A, **Song Y**, Dandurand A. “Real-world anti-seizure treatment, adverse event profile and management among people living with drug-resistant focal onset epilepsy in the United States.” American Epilepsy Society (AES) Annual Meeting, Orlando, FL (December 1–5, 2023)
- Ⓜ Fishman J, Kalilani L, **Song Y**, Swallow E, Wild I. “Dosage titration of AED treatments and related healthcare resource use and costs: a retrospective chart review in the US.” AMCP Annual Meeting, Denver, CO (March 27–30, 2017)
- Ⓜ **Song Y**, You NC, Song Y, Kang M, Hou L, Wallace R, Eaton C, Tinker L, Liu S. “Relation of dietary fat intake to peripheral leukocyte telomere length in postmenopausal women.” Society of Epidemiologic Research (SER), Boston, MA (June 20, 2013)
- Ⓜ **Song Y**, You NC, Goto A, Song Y, Hou L, Kroenke CH, Manson JE, Rohan TE, Tindle HA, Tinker LF, Liu S. “Unhealthy lifestyle in relation to peripheral leukocyte telomere length in postmenopausal women.” AHA Scientific Sessions, Los Angeles, CA (November 6, 2012)

JOURNAL REFEREE EXPERIENCE

Referee for *The BMJ*, the *Annals of Internal Medicine*, the *American Journal of Epidemiology*, the *Journal of Managed Care & Specialty Pharmacy*, *The American Journal of Clinical Nutrition*, *The Journal of Nutrition*, the *Journal of Diabetes*, and the *Asia Pacific Journal of Clinical Nutrition*.